June 1, 2020
With the start of school just around the corner, avoiding morning madness is on the minds of many parents—especially those whose kids have ADHD and struggle to get up, out, and on their way to school daily.
Relief may be in sight. According to an article on the Medscape Website, the U.S. Food and Drug Administration has approved a new medication. Jornay PM is formulated to be “taken in the evenings, instead of first thing in the morning to provide early-morning control of symptoms of ADHD.”
FDA approval was granted after two randomized trials showed that Jornay PM had a positive impact on ADHD symptoms in the morning and throughout the day. Together the studies evaluated 278 kids with ADHD, ages 6 to 12, some of whom were given Jornay PM while others were given a placebo. In a press release from Ironshore, maker of the new medication, Randy Sallee, MD and the company’s chief medical officer, explained the benefits:
Many parents of children with ADHD note that the early morning routine is often one of the most chaotic times of the day. The idea of dosing the medication the night before was our ‘moonshot’ solution to meeting this need. The approval of Jornay PM is a welcome treatment option for healthcare providers, patients, and their caregivers that may affect the way physicians think about ADHD treatment going forward.